|By PR Newswire||
|December 13, 2013 08:01 AM EST||
NEW YORK, December 13, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Zoetis Inc. (NYSE: ZTS), Allergan Inc. (NYSE: AGN), Clovis Oncology, Inc. (NASDAQ: CLVS), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and Mindray Medical International Limited (NYSE: MR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Zoetis Inc. Research Report
On December 10, 2013, Zoetis Inc.'s (Zoetis) stock declined 1.23%, ending the day at $31.36. Over the previous three trading sessions, shares of Zoetis declined 0.25%, compared to the Dow Jones Industrial Average which increased 0.96% during the same period. The Full Research Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Allergan Inc. Research Report
On December 10, 2013, Allergan Inc.'s (Allergan) stock declined 0.64%, ending the day at $97.41. Over the previous three trading sessions, shares of Allergan increased 0.94%, almost in line with the Dow Jones Industrial Average which increased 0.96% during the same period. The Full Research Report on Allergan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Clovis Oncology, Inc. Research Report
On December 3, 2013, Clovis Oncology, Inc. (Clovis) announced the pricing of an underwritten public offering of 2.0 million shares of its common stock at a price to the public of $57.50 per share. Clovis stated that all of the shares are being sold by certain existing stockholders who acquired the shares of the Company's common stock as consideration in connection with its acquisition of EOS (Ethical Oncology Science) S.p.A. According to Clovis, the selling stockholders granted J.P. Morgan Securities - the sole manager for the offering, a 30-day option to purchase up to an additional 300,000 shares of common stock from the selling stockholders to cover over-allotments, if any. The Company informed that the net proceeds from the sale of the common stock will be received by the selling stockholders and not by Clovis, and that the total number of shares of the Company's outstanding common stock will remain the same due to this offering. The Full Research Report on Clovis Oncology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Isis Pharmaceuticals, Inc. Research Report
Isis Pharmaceuticals, Inc. (Isis Pharmaceuticals) posted on the events page of their website that the Company's R&D Day has been rescheduled from December 12, 2013 to May 22, 2014. According to the Company, Isis' R&D Day will commence on the rescheduled day at 12:00 p.m. ET. Additional information and updates regarding the aforesaid event can be accessed through the Company's website. The Full Research Report on Isis Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Mindray Medical International Limited Research Report
Mindray Medical International Limited (Mindray) posted on the events page of their website that the Company's Annual Shareholder Meeting will be held on Tuesday, December 17, 2013 at 11:00 a.m. HKT. The Company informed that the aforesaid meeting will be held at its Hong Kong office: FLAT/RM 15-16 BLK 1 11/F, Grand Century, 193 Prince Edward West Road, Mongkok, KL HK. The Annual Shareholder Meeting is scheduled to commence at 11:00 a.m. Additional information and updates regarding the said event can be accessed through the Company's website. The Full Research Report on Mindray Medical International Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner